ESR1 and breast cancer: Accounting for approximately 15%-20% of instances of breast cancer (BC), triple-negative breast cancer (TNBC) is pathologically defined by a lack of targetable estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) (1, 2).